» Articles » PMID: 28085888

Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial

Abstract

Background: To increase the removal of middle-sized uremic toxins a new membrane with enhanced permeability and selectivity, called Medium Cut-Off membrane (MCO-Ci) has been developed that at the same time ensures the retention of albumin. Because many middle-sized substances may contribute to micro-inflammation we hypothesized that the use of MCO-Ci influences the inflammatory state in hemodialysis patients.

Methods: The randomized crossover trial in 48 patients compared MCO-Ci dialysis to High-flux dialysis of 4 weeks duration each plus 8 weeks extension phase. Primary endpoint was the gene expression of TNF-α and IL-6 in peripheral blood mononuclear cells (PBMCs), secondary endpoints were plasma levels of specified inflammatory mediators and cytokines.

Results: After four weeks of MCO-Ci the expression of TNF-α mRNA (Relative quantification (RQ) from 0.92 ± 0.34 to 0.75 ± 0.31, -18.5%, p<0.001)-α and IL-6 mRNA (RQ from 0.78 ± 0.80 to 0.60 ± 0.43, -23.1%, p<0.01) was reduced to a significantly greater extent than with High-flux dialyzers (TNF mRNA-RQ: -14.3%; IL-6 mRNA-RQ: -3.5%). After retransformation of logarithmically transformed data, measurements after MCO were reduced to 82% of those after HF (95% CI 74%-91%). 4 weeks use of MCO-Ci resulted in long-lasting change in plasma levels of several cytokines and other substances with a significant decrease for sTNFR1, kappa and lambda free light chains, urea and an increase for Lp-PLA2 (PLA2G7) compared to High-flux. Albumin levels dropped significantly after 4 weeks of MCO dialysis but increased after additional 8 weeks of MCO dialysis. Twelve weeks treatment with MCO-Ci was well tolerated regarding the number of (S)AEs. In the extension period levels of CRP, TNF-α-mRNA and IL-6 mRNA remained stable in High-flux as well as in MCO-Ci.

Conclusions: MCO-Ci dialyzers modulate inflammation in chronic HD patients to a greater extent compared to High-flux dialyzers. Transcription of pro-inflammatory cytokines in peripheral leukocytes is markedly reduced and removal of soluble mediators is enhanced with MCO dialysis. Serum albumin concentrations stabilize after an initial drop. These results encourage further trials with longer treatment periods and clinical endpoints.

Citing Articles

Impact of Albumin Leakage on the Mortality of Patients Receiving Hemodialysis or Online Hemodiafiltration.

Tashiro M, Okada K, Tanaka Y, Michiwaki H, Shima H, Inoue T J Clin Med. 2024; 13(7).

PMID: 38610630 PMC: 11012308. DOI: 10.3390/jcm13071865.


AKI in Adults with COVID-19 Infection: Mechanisms of Development and Role of Blood Filtration Devices in Treatment.

Hu J, Raina M, Mehta I, Sethi S, Soundararajan A, Bansal S Indian J Nephrol. 2024; 33(6):411-419.

PMID: 38174296 PMC: 10752394. DOI: 10.4103/ijn.ijn_51_23.


Medium cut-off dialyzer for middle molecular uremic toxins in AKI and chronic dialysis.

Fiorentino M, La Fergola F, De Rosa S J Nephrol. 2023; 37(1):23-37.

PMID: 37843731 PMC: 10920419. DOI: 10.1007/s40620-023-01771-0.


Expanded Hemodialysis ameliorates uremia-induced impairment of vasculoprotective KLF2 and concomitant proinflammatory priming of endothelial cells through an ERK/AP1/cFOS-dependent mechanism.

Zhao H, Wu D, Gyamfi M, Wang P, Luecht C, Pfefferkorn A Front Immunol. 2023; 14:1209464.

PMID: 37795100 PMC: 10546407. DOI: 10.3389/fimmu.2023.1209464.


The effects of medium cut-off and high-flux membranes on activated clotting time of patients on hemodialysis.

Lucca I, Armani R, Carvalho A, Manfredi S, Silva M, Gratao T Front Nephrol. 2023; 3:1133910.

PMID: 37675344 PMC: 10479637. DOI: 10.3389/fneph.2023.1133910.


References
1.
Lu P, Liu J, Pang X . Pravastatin inhibits fibrinogen- and FDP-induced inflammatory response via reducing the production of IL-6, TNF-α and iNOS in vascular smooth muscle cells. Mol Med Rep. 2015; 12(4):6145-51. DOI: 10.3892/mmr.2015.4149. View

2.
Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P . Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63(5):1934-43. DOI: 10.1046/j.1523-1755.2003.00924.x. View

3.
Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V . Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2008; 20(3):645-54. PMC: 2653681. DOI: 10.1681/ASN.2008060590. View

4.
Talmud P, Holmes M . Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2015; 35(11):2281-9. DOI: 10.1161/ATVBAHA.115.305234. View

5.
Hutchison C, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K . Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008; 9:11. PMC: 2564915. DOI: 10.1186/1471-2369-9-11. View